Literature DB >> 15943222

Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.

Allison Brashear1, Patrick Hogan, Maureen Wooten-Watts, Albert Marchetti, Raf Magar, John Martin.   

Abstract

Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943222     DOI: 10.1007/bf02850184

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  9 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb.

Authors:  Guy Molenaers; Anja Van Campenhout; Katrien Fagard; Jos De Cat; Kaat Desloovere
Journal:  J Child Orthop       Date:  2010-03-18       Impact factor: 1.548

Review 3.  Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.

Authors:  Carlo Colosimo; Dorina Tiple; Alfredo Berardelli
Journal:  Neurotox Res       Date:  2012-02-23       Impact factor: 3.911

4.  Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).

Authors:  Joseph Jankovic; Charles H Adler; P David Charles; Cynthia Comella; Mark Stacy; Marc Schwartz; Susan M Sutch; Mitchell F Brin; Spyridon Papapetropoulos
Journal:  BMC Neurol       Date:  2011-11-04       Impact factor: 2.474

5.  Long-time molecular dynamics simulations of botulinum biotoxin type-A at different pH values and temperatures.

Authors:  Xin Chen; Yuefan Deng
Journal:  J Mol Model       Date:  2007-02-27       Impact factor: 2.172

Review 6.  Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.

Authors:  Wallace A Marsh; Deirdre M Monroe; Mitchell F Brin; Conor J Gallagher
Journal:  BMC Neurol       Date:  2014-04-27       Impact factor: 2.474

Review 7.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

8.  Continuation of long-term care for cervical dystonia at an academic movement disorders clinic.

Authors:  Chandler E Gill; Neil D Manus; Michael W Pelster; Jason A Cook; Wallace Title; Anna L Molinari; David Charles
Journal:  Toxins (Basel)       Date:  2013-04-23       Impact factor: 4.546

9.  Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.

Authors:  Alexander Hawlitschka; Carsten Holzmann; Andreas Wree; Veronica Antipova
Journal:  Toxins (Basel)       Date:  2018-09-11       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.